Regeneron
Regeneron announces initial clinical data for COVID-19 antibody cocktail
December 18, 2020Medical Communications COVID-19, Regeneron, antibody
Regeneron Pharmaceuticals has announced that initial clinical data published in the New England Journal of Medicine shows that its antibody …
Regeneron halts Phase 1 study into ultra-rare disease due to patient deaths
November 3, 2020Manufacturing and Production, Research and Development Regeneron, clinical trials, garetosmab, pharma
Regeneron has slammed the brakes on its Phase 1 trial of garetosmab in the treatment of the ultra-rare condition fibrodysplasia …
Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma
September 18, 2020Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma
Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …
Regeneron seals $450m BARDA contract to scale up production of its COVID-19 vaccine
July 9, 2020Manufacturing and Production, Sales and Marketing BARDA, Operation Warp Speed, Regeneron, US, vaccine COVID-19
Regeneron has revealed that REGN-COV2, its two-antibody vaccine for the treatment and prevention of COVID-19, has been awarded a manufacturing …
Sanofi and Regeneron’s Libtayo shows durable responses in world’s most common skin cancer
May 5, 2020Manufacturing and Production, Research and Development Cancer, Libtayo, Regeneron, Sanofi
Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with …
Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer
April 29, 2020Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer
A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …
NICE shoots down Dupixent for severe asthma
March 9, 2020Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma
NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …
Novartis’ Beovu approved in Europe after outclassing Eylea in wet age-related macular degeneration
February 18, 2020Manufacturing and Production, Sales and Marketing Beovu, Eylea, Novartis, Regeneron, macular degeneration, pharma
The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet …
Sanofi and Regeneron’s Libtayo approved on NHS Scotland for cutaneous squamous cell carcinoma
February 11, 2020Manufacturing and Production, Sales and Marketing Libtayo, NHS, Regeneron, Sanofi, Scotland, nhs scotland, pharma
Scottish patients will now be able to access Sanofi and Regeneron’s Libtayo (cemiplimab) via the NHS after it became known …
FDA approves Novartis’ Beovu injection for wet age-related macular degeneration
October 8, 2019Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma
Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …
Regeneron invest $800 million into New York facilities
August 15, 2019Medical Communications East Greenbush, New York, Regeneron, pharma
Regeneron is investing $800 million into its New York production facilities. The firm is planning to build a four story …
Regeneron therapy halves LDL cholesterol levels in rare genetic condition
August 15, 2019Research and Development Regeneron, evinacumab, pharma, rare disease
Regeneron has reported a strong showing for its investigational angiopoietin-like 3 (ANGPTL3) antibody evinacumab in the treatment of the rare …
Libtayo becomes first EU-approved therapy for advanced cutaneous squamous cell carcinoma
July 2, 2019Manufacturing and Production, Sales and Marketing Europe, Libtayo, Regeneron, Sanofi, carcinoma, pharma
The European Commission has revealed that it has decided to award approval, albeit conditionally, to Sanofi and Regeneron’s Libtayo (cemiplimab) …
FDA expands indication for Eylea to cover all stages of diabetic retinopathy
May 14, 2019Manufacturing and Production Bayer, Eylea, FDA, Regeneron, approval, pharma
The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy. Regeneron chief scientific …
Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk
March 18, 2019Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent
Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …
